NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Reslizumab

Last Revision: December 21, 2020.

Estimated reading time: 1 minute

CASRN: 241473-69-8

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of reslizumab during breastfeeding. Because reslizumab is a large protein molecule with a molecular weight of 147,000 Da, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant's gastrointestinal tract. A task force respiratory experts from Europe, Australia and New Zealand found that reslizumab is possibly acceptable during breastfeeding.[1] Until more data become available, reslizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Asthma) Benralizumab, Omalizumab

References

1.
Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55:1901208. [PubMed: 31699837]

Substance Identification

Substance Name

Reslizumab

CAS Registry Number

241473-69-8

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Ixekizumab[Drugs and Lactation Database (...]
    Review Ixekizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Mepolizumab[Drugs and Lactation Database (...]
    Review Mepolizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Natalizumab[Drugs and Lactation Database (...]
    Review Natalizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Tildrakizumab[Drugs and Lactation Database (...]
    Review Tildrakizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pembrolizumab[Drugs and Lactation Database (...]
    Review Pembrolizumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...